Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Pfizer sues Chinese pharma firm over prostate cancer drug
Americas
Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California.   6 August 2024
Teva asks Fed Circ to reverse inhaler patents loss
Americas
Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.   1 August 2024
FDA prevails in Ipsen dispute over ‘biologic’ definition
Americas
Biopharmaceutical company insisted its cancer treatment should be considered a biologic | Panel finds “unfairly reductive” arguments “just don’t work” | FDA correct to reject Ipsen based on faulty scientific expertise.   30 July 2024
Pharma
New bill anticipated to depart from previous government’s light-touch approach to AI regulation | Attorneys fear “onerous or conflicting” requirements on pharma and biotech companies.   16 July 2024
Europe
New Secretary of State previously vowed Labour would harness AI and "put it to work for everyone from every background” | Starmer’s government expected to adopt a tougher position on AI regulation and laws | Proposed regulatory innovation office would expedite decisions for “fast, clear and consistent regulation”.   9 July 2024
Europe
UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in decision on Moderna’s EP 565 patent | Pfizer and German partner BioNTech on the hook for EP 949 | Opinion on Moderna’s COVID pledge also handed down.   4 July 2024
Americas
As SCOTUS pulls away from deference to federal agencies, issues such as non-competes and terminal disclaimers could be on shaky ground, finds Muireann Bolger.   2 July 2024
Americas
Womble Bond Dickinson’s new South Carolina partner previously led Dority & Manning’s chemical and life sciences group.   27 June 2024
Americas
Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move.   20 June 2024
Careers
The patent attorney’s expertise spans artificial intelligence, machine learning and medical devices.   23 May 2024

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.